IL17A and rheumatoid arthritis: Since recent research has revealed links between inflammatory signaling networks and the brain, autonomic nervous system, and spleen in both atherosclerosis and myocardial infarction [163], it is not surprising that additional studies found that targeted anti-inflammatory therapy lowered cardiovascular mortality in psoriasis (IL-17/IL-23 axis) [164–166], systemic lupus erythematosus (IL-17A signaling) [167], and rheumatoid arthritis (IL-6, TNF-α, and IL-17A cascades) [168, 169].